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Recent evidence suggests that oculomotor behaviours linked to cognitive performance can be a biomarker of Alzheimer’s disease (AD)
(Fernandez et al., 2018). Short-Term Memory Binding (STMB) declines in patients with AD dementia and in those at risk of dementia. STMB relies on brain regions
relevant to visual processing which are known to support oculomotor behaviours. A combined analysis of oculomotor responses during STMB can enhance the
sensitivity of the assessment of patients at risk of AD such as those with Mild Cognitive Impairment (MCI). We investigated this hypothesis.
Background
Results
Relative to controls, MCI patients displayed
significantly shorter fixation durations at baseline (Figure 2).
This was more pronounced during the encoding (t=-21.81)
than during retrieval (t=-4.34), and during the BC condition
(t=-16.98) than the UC condition (t=-13.82). MCI patients also
displayed larger saccades. Again, these were more
pronounced during the encoding (t=23.51) than during
retrieval (t=-9.06), and during the BC condition (t=21.46) than
the UC condition (t=-11.68).
Methods
Discussion
The sample comprised 42 controls (Age M=72SD=6.7; education = 12 years)
and 63 patients with MCI (Age 736.1; education = 12). The sample was recruited at the AXIS
Neuroscience Centre, Bahía Blanca, Argentina. The mean score of MCI patients in the MMSE
was 26.6 (SD = 2.2) vs. 29.7 (SD = 0.4) in controls. The mean score of MCI patients in the ACE-R
was 78.310.8 vs. 93.2 0.8 in controls. The mean score of MCI patients in the INECO’s Frontal
Screen was 18.45.2 vs. 27.01.1 in controls. Yesavage’s Geriatric Depression Scale (GDS) in MCI
was 8.52.8, cut-off point 9. Pfeffer functional activity in MCI was 6.11.5, cut-off 6. Hamilton’s
Anxiety Scale in MCI was 16.33.5, cut-off 18. Patients and controls were assessed with the
STMB test (Figure 1). Patients’ clinical status was reassessed one year after their enrolment in
the study.
Figure 1. Using eye-tracking technologies, we measured fixation and saccadic
amplitude in patients with MCI and in healthy controls while they performed the
STMBT. The STMBT assesses the ability to temporarily hold bicoloured objects
whose colours have to be 
remembered either as individual 
features (Unbound Colours - UC) or 
integrated within unified 
representations (Bound Colours - BC).
At follow up, 28 patients with MCI had progressed to dementia. Retrospective analysis (Figure 3) revealed the pattern above described was more pronounced in
MCI patients who latter developed dementia than in those who remained stable.
Figure 3. Retrospective analysis of eye-tracking data after follow-up.Figure 2. Eye-tracking data during STMB performance at baseline.
Taken together, the results above suggest that eye-tracking measures combined with cognitive markers for AD (STMB) can (1) enrich the
clinical phenotype of this type of dementia, (2) unveil novel features of AD dementia unknown to date, and (2) provide more sensitive tools which can detect and
trace aspects of such phenotype in people at risk, thus helping to ascertain the presence of the prodromal stages of the disease.
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